Efficacy and Safety of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis
Status:
Terminated
Trial end date:
2016-07-01
Target enrollment:
Participant gender:
Summary
Primary Objectives:
- To assess the efficacy of vatelizumab compared to placebo as measured by a reduction in
new contrast-enhancing lesions (CELs) in relapsing remitting multiple sclerosis (RRMS)
patients.
- To evaluate multiple doses of vatelizumab for a dose-response.
Secondary Objectives:
- To evaluate the safety and tolerability of vatelizumab compared to placebo.
- To evaluate the pharmacokinetics (PK) of vatelizumab.